.jpg)
READ-EB: Rapid Spectroscopic Evaluation, Assessment and Detection of Epidermolysis Bullosa
READ-EB is a portable, non-invasive diagnostic device that uses Raman spectroscopy combined with AI-driven SKiNET analysis to detect molecular and biochemical signatures associated with epidermolysis bullosa (EB) directly from the skin. The device rapidly identifies biomarkers of disease severity, skin integrity, and healing potential, providing objective, real-time results. Preclinical and early patient data demonstrate accurate classification of EB subtypes and assessment of skin lesion severity. The device integrates low-power lasers and a handheld optical probe, making it safe for repeated use in clinical and home settings.
READ-EB is designed for use in hospitals, clinics, and patient homes to provide rapid, point-of-care diagnostics and monitoring for epidermolysis bullosa. It enables clinicians to objectively assess disease progression, guide personalized treatment plans, monitor therapeutic response, and reduce reliance on invasive skin biopsies. Its portability and AI-assisted analysis make it suitable for rare-disease centres, telemedicine, and remote monitoring, improving patient outcomes, quality of life, and enabling scalable deployment for clinical trials and global patient care.
READ-EB is a handheld, standalone device, designed to be operated directly at the patient’s skin site. It does not require a desktop setup or floor-mounted support. Minimal stabilisation may be needed during measurements, but the device is fully portable and safe for repeated use in clinical, home, or research settings.
